References
- International Society for Pharmacoeconomics and Outcomes Research. 2017. ISPOR Good Practices for Outcomes Research Index. Retrieved from https://www.ispor.org/workpaper/practices_index.asp
- Campbell JD, McQueen RB, Briggs A. The “e” in cost-effectiveness analyses. A case study of omalizumab efficacy and effectiveness for cost-effectiveness analysis evidence. Annals of the American Thoracic Society 2014;11:S105-S111
- Dilokthornsakul P, Chaiyakunapruk N, Campbell JD. Does the use of efficacy or effectiveness evidence in cost-effectiveness analysis matter? Journal of Asthma 2017;54:17-23
- National Institute for Health and Care Excellence. Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia. 2016. Retrieved from London, UK: http://pad.res360.net/Content/Documents/NICE%20briefing%20paper%20for%20PCN%20-%20Evolocumab%20TA394%20.pdf
- Amgen. Amgen And Harvard Pilgrim Agree To First Cardiovascular Outcomes-Based Refund Contract For Repatha® (Evolocumab) 2017, May 2. Retrieved from https://www.amgen.com/media/news-releases/2017/05/amgen-and-harvard-pilgrim-agree-to-first-cardiovascular-outcomesbased-refund-contract-for-repatha-evolocumab/
- Hoyle M. Accounting for the drug life cycle and future drug prices in cost-effectiveness analysis. Pharmacoeconomics 2011;29:1-15